Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma

This study has been completed.
Sponsor:
Collaborator:
Schering-Plough
Information provided by:
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00591370
First received: December 26, 2007
Last updated: November 10, 2008
Last verified: November 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2008
  Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)